Solute carrier family 34 member 2 (SLC34A2), also known as Sodium-dependent phosphate transport protein 2B (Sodium-phosphate transport protein 2B), Na(+)-dependent phosphate cotransporter 2B, , Na(+)/Pi cotransporter 2B (NaPi-2b), is a protein that in humans is encoded by the SLC34A2 gene. SLC34A2 is a protein of 689 amino acids in humans. Its mRNA has been detected in many organs including testis, lungs, thyroid gland, salivary gland, small intestine, mammary gland, liver, and uterus. In the small intestine, SLC34A2 is expressed at the luminal brush border membrane in rats and humans, in the duodenum and jejunum, whereas in mice mostly in the ileum.
|Basic Information of SLC34A2|
|Protein Name||Sodium-dependent phosphate transport protein 2B|
|Aliases||Sodium-phosphate transport protein 2B, Na(+)-dependent phosphate cotransporter 2B, NaPi3b, Sodium/phosphate cotransporter 2B, Na(+)/Pi cotransporter 2B, NaPi-2b, Solute carrier family 34 member 2|
|Organism||Homo sapiens (Human)|
The abundance of SLC34A2 on the apical membrane of the small intestine is controlled by many factors. Early studies have shown that phosphate absorption across the intestinal epithelia is reduced during the suckling-weaning transition. This decrease in the phosphate absorbing capacity is consistent with an increase in the plasma levels of corticosterone, a glucocorticoid involved in intestinal maturation. Administration of corticosterone has been found to results in downregulation of SLC34A2 at the mRNA and protein level, which may be an effect on the ontogenic regulation of the cotransporter. As for the renal cotransporters, a decrease in dietary intake of phosphate leads to increased expression of SLC34A2 in the intestinal epithelia.
Fig.1 Transport mechanism of SLC34 proteins. (Wagner, 2014)
The article further elucidates the effects and mechanisms of SLC34A2 in the generation and development of lung cancer. It shows that the elevated expression of SLC34A2 inhibits the viability and invasion of A549 cells.
Authors in this group demonstrate that SLC34A2 could exert significantly suppressive effects on tumorigenesis and progression of human non-small cell lung cancer, which may provide new insights for further understanding the early pathogenesis of human NSCLC.
The article reports that knockdown of SLC34A2 inhibits proliferation and migration by suppressing activation of the PI3K/AKT signaling pathway in hepatocellular carcinoma (HCC) cells. The results indicate that SLC34A2 may be a potential therapeutic target for the treatment of HCC.
The article reveals that NaPi-IIb is the only luminal Na(+) -dependent Pi transporter in the murine ileum and its absence is fully compensated for in adult females by a mechanism involving the bone-kidney axis.
The article reports that anti-NaPi2b ADC is effective in mouse ovarian and non-small cell lung cancer (NSCLC) tumor xenograft models, providing an effective new therapy for the treatment of NSCLC.
To obtain the soluble and functional target protein, the versatile Magic™ membrane protein production platform in Creative Biolabs enables many flexible options, from which you can always find a better match for your particular project. Aided by our versatile Magic™ anti-membrane protein antibody discovery platform, we also provide customized anti-SLC34A2 antibody development services.
As a leading service provider, Creative Biolabs is proud to present our professional service in membrane protein preparation and help you with the research of membrane proteins. Please do not hesitate to inquire us for more details.